JP2020506192A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506192A5
JP2020506192A5 JP2019541718A JP2019541718A JP2020506192A5 JP 2020506192 A5 JP2020506192 A5 JP 2020506192A5 JP 2019541718 A JP2019541718 A JP 2019541718A JP 2019541718 A JP2019541718 A JP 2019541718A JP 2020506192 A5 JP2020506192 A5 JP 2020506192A5
Authority
JP
Japan
Prior art keywords
compound according
och
optionally substituted
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019541718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506192A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/052537 external-priority patent/WO2018141854A1/en
Publication of JP2020506192A publication Critical patent/JP2020506192A/ja
Publication of JP2020506192A5 publication Critical patent/JP2020506192A5/ja
Pending legal-status Critical Current

Links

JP2019541718A 2017-02-02 2018-02-01 インフルエンザウイルスを阻害するためのピペラジン誘導体 Pending JP2020506192A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762453673P 2017-02-02 2017-02-02
US62/453,673 2017-02-02
EP17156448 2017-02-16
EP17156448.7 2017-02-16
PCT/EP2018/052537 WO2018141854A1 (en) 2017-02-02 2018-02-01 Piperazine derivatives for influenza virus inhibition

Publications (2)

Publication Number Publication Date
JP2020506192A JP2020506192A (ja) 2020-02-27
JP2020506192A5 true JP2020506192A5 (enExample) 2021-03-11

Family

ID=61192896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019541718A Pending JP2020506192A (ja) 2017-02-02 2018-02-01 インフルエンザウイルスを阻害するためのピペラジン誘導体

Country Status (5)

Country Link
US (1) US11040963B2 (enExample)
EP (1) EP3577107A1 (enExample)
JP (1) JP2020506192A (enExample)
AU (1) AU2018216954B2 (enExample)
CA (1) CA3052353A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10452480B2 (en) 2017-05-25 2019-10-22 Micron Technology, Inc. Memory device with dynamic processing level calibration
US10140040B1 (en) 2017-05-25 2018-11-27 Micron Technology, Inc. Memory device with dynamic program-verify voltage calibration
US10664194B2 (en) 2018-05-16 2020-05-26 Micron Technology, Inc. Memory system with dynamic calibration using a variable adjustment mechanism
US10990466B2 (en) 2018-06-20 2021-04-27 Micron Technology, Inc. Memory sub-system with dynamic calibration using component-based function(s)
US11188416B2 (en) 2018-07-12 2021-11-30 Micron Technology, Inc. Enhanced block management for a memory sub-system
US11113129B2 (en) 2018-07-13 2021-09-07 Micron Technology, Inc. Real time block failure analysis for a memory sub-system
US10936246B2 (en) 2018-10-10 2021-03-02 Micron Technology, Inc. Dynamic background scan optimization in a memory sub-system
BR112022002387A2 (pt) * 2019-12-20 2022-09-06 Landos Biopharma Inc Composto da fórmula z-y-q-y' ou um sal ou éster farmaceuticamente aceitável do mesmo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430861T2 (de) * 1993-04-07 2003-01-23 Otsuka Pharmaceutical Co., Ltd. N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009117444A1 (en) 2008-03-17 2009-09-24 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
BR112012002331A2 (pt) 2009-08-05 2019-09-24 Versitech Ltd composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
ES2533068T3 (es) 2010-09-08 2015-04-07 Bristol-Myers Squibb Company Nuevos análogos de piperazina como antivirales de influenza de amplio espectro
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
BR112014000263B1 (pt) 2011-07-14 2022-01-18 Janssen Vaccines & Prevention B.V. Anticorpo isolado capaz de se ligar especificamente à proteína hemaglutinina (ha) dos subtipos de vírus influenza b, e, composição farmacêutica que o compreende

Similar Documents

Publication Publication Date Title
JP2020506192A5 (enExample)
RU2437877C2 (ru) Новые производные тиофена в качестве агонистов рецептора s1p1/edg1
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
RU2419626C2 (ru) Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
JP2010513322A5 (enExample)
JP2010516635A5 (enExample)
JP2007519692A5 (enExample)
JP2020533352A5 (enExample)
JP2005500311A5 (enExample)
JP2017523972A5 (enExample)
RU2004133041A (ru) Производные бензоксазинона, их получение и применение в качестве лекарственных средств
RU2004111285A (ru) Оксазолидинон и/или изоксазолин в качестве антибактериальных средств
JP2013510883A5 (enExample)
RU2007106928A (ru) Производные бензилтриазолона в качестве ненуклеозидных ингибиторов обратной транскриптазы
CA2494832A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
JP2015523980A5 (enExample)
JP2018503661A5 (enExample)
KR920021541A (ko) 벤조푸란 유도체
JP2019519616A5 (enExample)
TR199802253T2 (xx) Alkilaminobenzotiazol ve benzoksazol t�revleri
JP2005519885A5 (enExample)
RU2221788C2 (ru) Оксоциклические соединения мочевины, фармацевтическая композиция, способ лечения
JP2018510202A5 (enExample)
CA2547347A1 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
PE20120732A1 (es) Agonistas del receptor de esfingosina-1-fosfato